COVID-19 Patient with Encephalitis as an Initial Clinical Presentation

A growing number of extrapulmonary manifestations were described during COVID-19 pandemic. COVID-19 has both acute and long-term neurological complications affecting the central and peripheral nervous system. While acute encephalopathy was the most common clinically diagnosed neurological sign, the least common were meningitis and/or encephalitis. The patient was a 68-yearold previously healthy man who presented to the emergency department with symptoms of fever, headache, confusion, meaningless speech, and behavioral disorders. We present a COVID-19 patient with encephalitis as an initial clinical presentation who was treated with dexamethasone, IVIG and tocilizumab with a rapid neurological improvement. This report highlights COVID-19 encephalitis which is a rare form of the neurological involvement of COVID-19 and discusses diagnostic and therapeutic approaches

A Cause of Fungemia in A Patient with Hematological Malignancy: Blastoschizomyces capitatus

Blastoschizomyces capitatus is a rare fungal pathogen that may lead to severe and fatal infections in patients with hematological malignancies.The risk factors for infections with this pathogen are hematological malignancy, cytotoxic chemotherapy, corticosteroid use, intravascular catheter use, and broad spectrum antibiotic use. In this case report, fungemia and pneumoniae due to B. capitatus is reported in a patient who is diagnosed with acute lymphoblastic leukemia and receiving chemotheraphy. Blood cultures became negative after treatment with liposomal amphotericin B. In immunosupressed patients with severe fungal infection, B. capitatus should be kept in mind and should be considered in the choice of treatment. Further studies are required for the determination of antifungal susceptibilities and susceptibility breakpoints for B. capitatus